A new double-blind, placebo-controlled feasibility trial from Australian university researchers found that a 1:1 THC:CBD cannabis oil was well-tolerated and associated with meaningful reductions in fibromyalgia pain, improved sleep quality, and better overall function. Seventy percent of participants on the active oil achieved at least a 30% reduction in pain. The findings are preliminary but clinically suggestive, and they add to a growing body of evidence that full-spectrum cannabinoid formulations may be particularly relevant for fibromyalgia patients who have exhausted conventional options.
Table of Contents
Cannabis Oil for Fibromyalgia Pain and Sleep: What a New Clinical Trial Found
A peer-reviewed feasibility trial published this week in Pain Research and Management put a 1:1 THC:CBD cannabis oil to a rigorous double-blind test in fibromyalgia patients. The results, though preliminary, show a clinically meaningful gap between the active treatment and placebo on pain, sleep, and fibromyalgia impact scores. Here is what the study actually measured, what it did not, and why it matters for patients living with fibromyalgia in Massachusetts and across the country.
Dealing with a condition like this?
Dr. Caplan has worked with 30,000+ patients on conditions like this. A consultation starts with your specific situation — not a generic protocol.
Book a consultation →This is a human DBPCT involving a patient population frequently seen at CED Clinic. Fibromyalgia, chronic widespread pain, and sleep dysfunction are among the most common presentations in our cannabis medicine practice. The formulation tested (1:1 THC:CBD oil, 10 mg/mL each) is pharmacologically consistent with formulations we discuss in clinical consultations.
- What the trial measured, how it was designed, and who conducted it
- How the 1:1 THC:CBD oil performed on pain, sleep, and fibromyalgia impact versus placebo
- What the study’s limitations mean for interpreting the results
- How this fits with the broader clinical landscape for fibromyalgia treatment
- What patients and clinicians in New England should know now
- ❇️ A 16-week double-blind trial in 24 fibromyalgia patients found 1:1 THC:CBD cannabis oil was well-tolerated, with no serious adverse events and a 92% completion rate.
- ❇️ Seventy percent of patients on cannabis oil achieved at least a 30% pain reduction, compared to 20% on placebo after the titration period.
- ❇️ Sleep quality and fibromyalgia impact scores also favored the active treatment group in a clinically meaningful way.
- ❇️ This was a small feasibility study, not powered to prove efficacy. Larger trials are needed, but the signal is real and the methodology sound.
| Study Type | Double-blind, randomized, placebo-controlled feasibility trial |
| Sample Size | 24 adults with fibromyalgia (all female; 22 completed the trial) |
| Duration | 16 weeks: 4-week dose titration followed by 12 weeks of stable dosing |
| Intervention | 1:1 THC:CBD cannabis oil (10 mg/mL each) versus matched placebo |
| Primary Outcome | Feasibility: retention, adherence, and safety in preparation for a larger trial |
| Key Pain Finding | 70% of cannabis oil group achieved ≥30% pain reduction vs. 20% in placebo (post-titration); 40% placebo by Week 12 |
| Key Impact Finding | Clinically meaningful fibromyalgia impact improvement in 40% of active group vs. 10% placebo at Week 12 |
| Safety | No serious adverse events; common side effects: somnolence, dizziness, fatigue, nausea, dry mouth |
| Journal | Pain Research and Management (Wiley Open Access) — Published May 16, 2026 |
| Institutions | Southern Cross University, Griffith University, Gold Coast University Hospital (Australia). PI: Dr. Janet Schloss |
Fibromyalgia affects an estimated four million adults in the United States, the large majority of them women. It sits at a frustrating intersection in medicine: objectively real, often debilitating, and notoriously resistant to conventional treatments. First-line options like duloxetine, milnacipran, and pregabalin help some patients meaningfully, but many patients do not find adequate relief. They land in our office looking for something different.
The research base for cannabinoids in fibromyalgia has been building slowly, and this trial represents one of the most methodologically rigorous contributions to date. The fact that it used a double-blind design with a matched placebo oil, tracked participants for 16 weeks, achieved a 92% completion rate, and reported no serious adverse events is itself significant. These are not easy numbers to produce in cannabis research, where blinding is notoriously difficult. A well-run feasibility study like this one is how responsible large-scale trials get built.
The trial enrolled 24 adults, all women, meeting diagnostic criteria for fibromyalgia. Participants were randomized to receive either the cannabis oil or a matched placebo and spent four weeks gradually increasing their dose before settling into a stable 12-week dosing period. The primary goal was not to prove efficacy but to confirm that a larger, definitive trial was feasible. On that primary question, the answer was largely yes: retention was high, adherence was near-complete, and the safety profile was acceptable.
The secondary outcomes were where the clinical story got interesting. At the post-titration assessment, 70% of participants receiving the active cannabis oil had achieved at least a 30% reduction in pain intensity, compared with 20% of the placebo group. At Week 12, the placebo group’s rate rose to 40%, narrowing the gap somewhat, but the treatment group remained ahead. Forty percent of the active group reached a clinically meaningful improvement in the Fibromyalgia Impact Questionnaire score, versus 10% in the placebo group. Sleep quality improved in the active group. Physical functioning and social functioning improved. Fatigue, anxiety, and depression did not reach statistical significance, which the authors noted and which aligns with the common clinical observation that cannabinoids tend to affect pain and sleep more reliably than mood in this population.
The authors are appropriately candid about the study’s limitations, and any clinician reading the paper should be too. Twenty-four participants is a small cohort, and the resulting confidence intervals are wide. Wide confidence intervals mean the true treatment effect could be larger or smaller than what the numbers suggest. We do not yet know.
All participants were women, which reflects the demographic reality of fibromyalgia but limits generalizability. The trial was conducted in Australia under specific prescribing conditions and with specific products not identical to what is available in Massachusetts or other U.S. states. The dosing protocol, a titration to a stable 10 mg/mL dose of each cannabinoid, was standardized but may not reflect optimal dosing for every patient. And because recruitment fell short of the planned 36 participants (largely due to geographic barriers and Australian THC driving regulations), the trial has even less statistical power than originally intended.
None of this invalidates the findings. It contextualizes them. The signal is there. What the field needs now is the larger, adequately powered trial the authors call for.
How This Fits With What We Already Know
The existing evidence for cannabis in fibromyalgia has come primarily from observational studies, retrospective chart reviews, and smaller RCTs. A 2020 trial by Habib and Artul found that cannabis users with fibromyalgia reported significant improvements in pain and quality of life. A 2019 Israeli observational study of over 300 patients reported meaningful pain score reductions over six months. The picture that emerges from the aggregate is consistent: cannabis appears to reduce fibromyalgia symptom burden in a meaningful subset of patients, with pain and sleep as the most responsive domains.
What makes this new trial notable is not the magnitude of the effect but the methodology. A 1:1 THC:CBD formulation was chosen deliberately, reflecting current thinking that CBD may modulate some of the adverse effects of THC while contributing its own anti-inflammatory and modulatory activity on pain pathways. The balance matters because fibromyalgia is thought to involve central sensitization, a state in which the central nervous system amplifies pain signals beyond what peripheral tissue damage would justify. Both THC and CBD have known effects on pain processing, and their combined use at equal ratios addresses this mechanism from multiple angles.
At CED Clinic, we have written extensively about medical cannabis for chronic pain and the evolving evidence base. The pharmacological rationale for using balanced cannabinoid formulations in central sensitization conditions like fibromyalgia has been well-established in preclinical and observational work. This trial adds a prospective, controlled dimension to that rationale.
Fibromyalgia is one of the most underserved conditions in American medicine. Patients come to us after years of cycling through medications that helped a little or not at all, or that helped for a while and then stopped. They come carrying diagnoses they were told to manage, not treat. So when I look at a study like this one and see 70% of participants achieving at least a 30% pain reduction, I notice something. That is not a small effect size. In trials of approved fibromyalgia medications, response rates at that threshold are often in the 40 to 50 percent range. This is a small feasibility study, yes. But the signal is the kind that earns a proper large-scale trial.
The 1:1 THC:CBD formulation is clinically intuitive. CBD softens some of the intoxicating and anxiogenic effects of THC, which matters for fibromyalgia patients who may be sensitive to psychoactive effects. At the same time, THC brings analgesic and sleep-promoting properties that CBD alone does not consistently deliver. There is a reason the cannabis medicine field has moved toward balanced formulations for chronic pain. This trial gives that preference a prospective, placebo-controlled foundation.
What I pay particular attention to in studies like this one is the safety profile. Twenty-four patients, 16 weeks, no serious adverse events. Side effects were mild and consistent with what we already know: some somnolence, some dizziness early in the titration phase, dry mouth. These are manageable, particularly with proper titration guidance. The 92% completion rate tells me patients found the treatment acceptable. That matters enormously in a population that has been failed by so many other treatments.
For patients in Massachusetts asking whether cannabis could help their fibromyalgia, my answer has not changed: this is a conversation worth having. What this trial adds is a stronger scientific foundation for having it. The next step is a larger trial. In the meantime, patients who are suffering and who have not found relief elsewhere deserve access to a clinician who can help them weigh this option carefully, with the evidence, the pharmacology, and their individual history in front of both of them.
What a Careful Reader Should Take Away
This study is a feasibility trial. That framing is not a euphemism for “inconclusive.” Feasibility trials serve a specific scientific purpose: they determine whether a larger definitive trial is worth running. On that question, this study answers yes. High adherence, acceptable safety, and consistent directional trends across multiple secondary endpoints are exactly the signals that justify the resources of a larger study.
For patients, the takeaway is that the evidence for cannabis in fibromyalgia continues to develop and is trending in a positive direction. The specific formulation studied here, a balanced 1:1 THC:CBD oil, is not unique or proprietary. Similar formulations are available through licensed medical cannabis programs, including in Massachusetts, though the precise product composition and dosing protocol vary. What is consistent is the pharmacological principle: combining THC and CBD in roughly equal measure to address both the central sensitization underlying fibromyalgia and the sleep disruption that compounds it.
For clinicians, the study reinforces that a well-designed cannabis trial in fibromyalgia is achievable and that the dropout and safety concerns that have historically discouraged investigators appear manageable with proper patient selection and titration protocols. The field needs more studies like this one, only larger. Experienced cannabis medicine programs like those offered at CED Clinic can be valuable partners in that kind of research.
If you or someone you know is living with fibromyalgia and has not found adequate relief through conventional means, our team at CED Clinic is experienced in evaluating cannabis-based care for fibromyalgia and discussing the current evidence in the context of your individual history and goals.
💬 Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
Schloss J, et al. (2026). A feasibility randomized, double-blind, placebo-controlled trial of 1:1 THC:CBD cannabis oil in fibromyalgia. Pain Research and Management. Wiley Open Access. Published May 16, 2026. DOI: 10.1155/prm/7311235
Conducted by researchers from Southern Cross University’s National Centre for Naturopathic Medicine, Griffith University, and Gold Coast University Hospital, Australia.
Frequently Asked Questions
What did this clinical trial actually study?
This was a double-blind, randomized, placebo-controlled feasibility trial. It enrolled 24 women with fibromyalgia and assigned them to either a cannabis oil containing equal amounts of THC and CBD (10 mg/mL each) or a matched placebo. The trial ran for 16 weeks, including a 4-week dose titration phase and a 12-week stable dosing phase. The primary goal was to determine whether a larger, definitive efficacy trial would be feasible. Secondary goals included assessing pain, sleep, fibromyalgia impact, and quality of life.
What were the main results for pain relief?
At the end of the dose titration phase, 70% of participants in the cannabis oil group had achieved at least a 30% reduction in pain intensity, compared to 20% in the placebo group. By Week 12 of stable dosing, the placebo group’s rate had risen to 40%, while the cannabis oil group remained ahead. A 30% reduction in pain is a commonly used clinical threshold for meaningful pain relief in chronic pain research.
Did the cannabis oil improve sleep?
Yes. Researchers reported improvements in sleep quality among participants receiving the THC:CBD cannabis oil. Fibromyalgia is commonly associated with non-restorative sleep, and addressing sleep disruption is considered an important part of managing the overall symptom burden. The sleep findings in this trial are consistent with what has been observed in other cannabis studies for chronic pain conditions.
Was the cannabis oil safe?
The treatment was well-tolerated. No serious adverse events were reported in either group. The most common side effects in the cannabis oil group were somnolence (drowsiness), dizziness, fatigue, nausea, and dry mouth. These are consistent with the known side effect profile of THC at moderate doses and are typically manageable, particularly with careful dose titration. Twenty-two of the 24 participants completed the full 16-week trial, which is a strong adherence rate.
Why does the formulation use equal amounts of THC and CBD?
A 1:1 THC:CBD ratio was chosen based on pharmacological reasoning. THC provides analgesic (pain-relieving) and sleep-promoting effects but can also cause anxiety or cognitive side effects in some patients. CBD has its own anti-inflammatory and modulatory properties and appears to reduce some of the adverse effects associated with THC. Together, at equal ratios, they may provide a more balanced therapeutic profile. This formulation approach is consistent with current thinking in cannabis medicine for chronic pain conditions involving central sensitization, like fibromyalgia.
What are the limitations of this study?
The main limitations are the small sample size (24 participants), the all-female sample, and the fact that recruitment fell short of the planned 36 participants due to geographic and regulatory barriers in Australia. Small samples produce wide confidence intervals, meaning the true treatment effect could be larger or smaller than the observed results. The study was designed as a feasibility trial, not a definitive efficacy trial, so it is not appropriate to draw firm efficacy conclusions from the data alone. The authors call for a larger, adequately powered trial to confirm the findings.
Is cannabis available for fibromyalgia in Massachusetts?
Yes. Fibromyalgia is a qualifying condition for medical cannabis in Massachusetts, and CED Clinic provides physician evaluations and guidance for patients seeking cannabis-based care. Massachusetts has a well-developed medical cannabis program with access to a wide range of formulations, including oils and tinctures with varying THC and CBD ratios. Patients interested in exploring this option should speak with a knowledgeable cannabis medicine physician who can evaluate their history and help them weigh the evidence.
Did the study find any effect on anxiety or depression?
No clear statistically significant improvements were observed for fatigue, anxiety, or depression in this trial. This is worth noting, particularly given that fibromyalgia frequently co-occurs with mood and fatigue symptoms. The authors acknowledged this finding. It is consistent with the broader literature, which generally shows stronger cannabinoid effects on pain and sleep than on anxiety or depression in chronic pain populations. This does not mean cannabis is ineffective for mood in fibromyalgia, only that this small trial did not detect that effect.
What does “feasibility trial” mean and why does it matter?
A feasibility trial is designed to answer a specific set of questions before a larger, definitive study is conducted: Can we recruit enough patients? Will they stay in the study? Is the treatment safe enough to test at scale? Will the data collection methods work? This trial answered those questions positively. High retention (92%), high adherence (all participants took at least 90% of doses), and no serious adverse events mean the foundation exists for a properly powered efficacy trial. Feasibility trials are an important and often underappreciated step in the responsible development of clinical evidence.
How does this study compare to other cannabis research in fibromyalgia?
Prior fibromyalgia cannabis studies have included observational cohorts, retrospective chart reviews, and a few smaller randomized trials. A 2019 Israeli observational study of over 300 fibromyalgia patients reported meaningful improvements in pain with medical cannabis over six months. A 2020 RCT by Habib and Artul found significant improvements in quality of life and pain. The current study adds a double-blind design, a matched placebo, and a specific 1:1 THC:CBD formulation, making it one of the more methodologically rigorous contributions to this area. The results are directionally consistent with what the prior evidence suggested.